A new drug is being hailed as a turning point in the fight against Alzheimer’s after a groundbreaking trial found it slows the progression of the disease.
A study found that the use of donanemab slowed “clinical decline” by up to 35 per cent, allowing those diagnosed to continue performing daily tasks with independence such as managing their finances, taking medication or shopping.
